# Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

> **NCT02799862** · — · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 408 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Nab-Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02799862
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-29
- **Primary completion:** 2019-12-07
- **Final completion:** 2021-06-06
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02799862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02799862, "Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02799862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*